Table 1.

Patient characteristics for immune and viral correlate analysis

Characteristic	Per Protocol (PP) (N=21)a	Intent To Treat (ITT) (N=5)b	Total Evaluable (N=26)	P-valuesc
Median age, years (range)	48 (34-62)	51 (26-56)	49 (26-62)	0.79
Race, N (%)
White	14 (67)	4 (80)	18 (69)	1.00
African American	4 (19)	1 (20)	5 (19)
Asian	2 (9)	0 (0)	2 (8)
Other	1 (5)	0 (0)	1 (4)
Ethnicity, N (%)
Non-Hispanic	14 (67)	4 (80)	18 (69)	1.00
Hispanic	7 (33)	1 (20)	8 (31)
Histology, N (%)
Squamous cell carcinoma	19 (90)	4 (80)	23 (88)	0.49
Adenosquamous	1 (5)	0 (0)	1 (4)
Adenocarcinoma	1 (5)	1 (20)	2 (8)
Lymph node involvement, N (%)
Pelvic	15 (71)	3 (60)	18 (69)	0.63
Pelvic and Para-aortic	6 (29)	2 (40)	8 (31)
FIGOd Stage, N (%)
1B	3 (14)	1 (20)	4 (15)	0.69
IIA	1 (5)	1 (20)	2 (8)
IIB	11 (52)	2 (40)	13 (50)
IIIB	5 (24)	1 (20)	6 (23)
IVA	1 (5)	0 (0)	1 (4)
HLA-A*0201 status, N (%)
Positive	8 (38)	1 (20)	9 (35)	0.63
Negative	13 (62)	4 (80)	17 (65)
Ipilimumab Dose Level, N (%)
3 mg/kg	3 (14)	0 (0)	3 (12)	1.00
10 mg/kg	18 (86)	5 (100)	23 (88)
Ipilimumab Doses, N (%)
2	3 (14)	0 (0)	3 (14)	<0.001
4	18 (86)	0 (0)	18 (86)

^aPP patients received CRT and ≥ 2 doses ipilimumab

^bITT patients received CRT only

^cComparing PP patients vs. ITT patients, using the Wilcoxon rank sum test and Fisher’s exact test where appropriate

^dFIGO, International Federation of Gynecology and Obstetrics